Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.

Pathology oncology research : POR - 1 Jan 2021

Nelhűbel Györgyi A, Cserepes Mihály, Szabó Balázs, Türk Dóra, Kárpáti Adél, Kenessey István, Rásó Erzsébet, Barbai Tamás, Hegedűs Zita, László Viktória, Szokol Bálint, Dobos Judit, Őrfi László, Tóvári József

Abstract excerpt

Background: Anti-EGFR antibody therapy is still one of the clinical choices in head and neck squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab resistance questioned its effectiveness and reduced its applicability. Although several possible reasons of resistance against the antibody treatment and alternative therapeutic proposals have been described (EGFR alterations, activation of other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cetuximab
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Head and Neck Neoplasms

Share to Mice, SCID

Share to Piperazines

Share to Proto-Oncogene Proteins c-met

Share to Squamous Cell Carcinoma of Head and Neck

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 34257586
DOI: 10.3389/pore.2021.620256
PMCID: PMC8262169

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.PMID 34257586Read ↗

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism.Semantic proximity Read ↗

Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance.Semantic proximity Read ↗

Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.Semantic proximity Read ↗

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.Semantic proximity Read ↗

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read ↗

EGFR Mutations in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.Semantic proximity Read ↗

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.Semantic proximity Read ↗

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.